| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 18 | 2024 | 715 | 3.480 |
Why?
|
| Chemoradiotherapy | 9 | 2024 | 326 | 1.860 |
Why?
|
| Cryoelectron Microscopy | 8 | 2022 | 114 | 1.570 |
Why?
|
| Esophageal Neoplasms | 6 | 2025 | 344 | 1.420 |
Why?
|
| Nelfinavir | 4 | 2024 | 6 | 1.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 2544 | 1.240 |
Why?
|
| Adenocarcinoma | 6 | 2021 | 1173 | 1.220 |
Why?
|
| Membrane Proteins | 4 | 2023 | 1264 | 0.990 |
Why?
|
| Capecitabine | 5 | 2021 | 97 | 0.960 |
Why?
|
| Models, Molecular | 11 | 2025 | 1353 | 0.950 |
Why?
|
| Immunoglobulin Fab Fragments | 4 | 2025 | 86 | 0.930 |
Why?
|
| Symporters | 2 | 2024 | 112 | 0.900 |
Why?
|
| Antibodies | 3 | 2022 | 348 | 0.850 |
Why?
|
| Paclitaxel | 2 | 2024 | 479 | 0.790 |
Why?
|
| Bile Acids and Salts | 2 | 2024 | 77 | 0.760 |
Why?
|
| Single-Domain Antibodies | 1 | 2021 | 8 | 0.720 |
Why?
|
| Consensus | 2 | 2020 | 368 | 0.700 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 39 | 0.680 |
Why?
|
| Maltose-Binding Proteins | 2 | 2018 | 31 | 0.660 |
Why?
|
| Cell Surface Display Techniques | 3 | 2020 | 16 | 0.650 |
Why?
|
| Deoxycytidine | 5 | 2024 | 208 | 0.640 |
Why?
|
| Carboplatin | 1 | 2021 | 322 | 0.630 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 146 | 0.570 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 338 | 0.560 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 333 | 0.560 |
Why?
|
| Escherichia coli K12 | 1 | 2018 | 4 | 0.550 |
Why?
|
| Protein Conformation | 7 | 2022 | 914 | 0.550 |
Why?
|
| Maltose | 1 | 2018 | 33 | 0.540 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 22 | 0.540 |
Why?
|
| Molecular Probes | 1 | 2018 | 37 | 0.540 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.510 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 245 | 0.500 |
Why?
|
| Escherichia coli Proteins | 1 | 2018 | 179 | 0.490 |
Why?
|
| Protein Binding | 7 | 2025 | 1534 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1053 | 0.470 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2024 | 131 | 0.470 |
Why?
|
| United Kingdom | 6 | 2025 | 190 | 0.460 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 21 | 0.460 |
Why?
|
| Calmodulin | 1 | 2015 | 50 | 0.450 |
Why?
|
| Clinical Protocols | 1 | 2015 | 154 | 0.420 |
Why?
|
| Metformin | 4 | 2022 | 125 | 0.420 |
Why?
|
| Humans | 50 | 2025 | 93515 | 0.420 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 2303 | 0.410 |
Why?
|
| Fluorouracil | 2 | 2017 | 524 | 0.370 |
Why?
|
| Preoperative Care | 1 | 2015 | 406 | 0.370 |
Why?
|
| Peptide Library | 4 | 2022 | 84 | 0.360 |
Why?
|
| Crystallography, X-Ray | 4 | 2020 | 520 | 0.360 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 284 | 0.330 |
Why?
|
| G-Protein-Coupled Receptor Kinase 1 | 2 | 2021 | 4 | 0.330 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 29 | 0.320 |
Why?
|
| Pandemics | 3 | 2020 | 873 | 0.320 |
Why?
|
| Rhodopsin | 2 | 2021 | 21 | 0.310 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2009 | 46 | 0.300 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2020 | 204 | 0.300 |
Why?
|
| Polymers | 3 | 2023 | 218 | 0.300 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 85 | 0.300 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2019 | 17 | 0.290 |
Why?
|
| Combined Modality Therapy | 6 | 2019 | 1723 | 0.290 |
Why?
|
| Antioxidants | 2 | 2020 | 231 | 0.270 |
Why?
|
| Wound Healing | 2 | 2020 | 373 | 0.260 |
Why?
|
| Aged | 10 | 2024 | 20434 | 0.260 |
Why?
|
| Biotinylation | 2 | 2018 | 42 | 0.250 |
Why?
|
| Thermodynamics | 5 | 2019 | 325 | 0.250 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 299 | 0.250 |
Why?
|
| DNA Damage | 2 | 2019 | 389 | 0.250 |
Why?
|
| Disease-Free Survival | 7 | 2022 | 1170 | 0.240 |
Why?
|
| Maximum Tolerated Dose | 2 | 2024 | 259 | 0.240 |
Why?
|
| Amino Acid Sequence | 5 | 2021 | 2012 | 0.230 |
Why?
|
| Health Priorities | 1 | 2025 | 26 | 0.230 |
Why?
|
| Receptors, CXCR | 1 | 2025 | 4 | 0.230 |
Why?
|
| Arrestins | 1 | 2025 | 11 | 0.230 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2025 | 18 | 0.230 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2016 | 97 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2020 | 317 | 0.220 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 41 | 0.220 |
Why?
|
| Biological Transport | 2 | 2023 | 404 | 0.220 |
Why?
|
| Recombinant Proteins | 3 | 2019 | 988 | 0.220 |
Why?
|
| Middle Aged | 12 | 2024 | 27573 | 0.220 |
Why?
|
| Protease Inhibitors | 1 | 2024 | 71 | 0.210 |
Why?
|
| Lipopeptides | 1 | 2024 | 20 | 0.210 |
Why?
|
| Albumins | 1 | 2024 | 123 | 0.210 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2023 | 4 | 0.200 |
Why?
|
| Hepatitis B | 1 | 2024 | 77 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 7061 | 0.200 |
Why?
|
| Sunscreening Agents | 1 | 2023 | 10 | 0.190 |
Why?
|
| Mannosyltransferases | 1 | 2023 | 7 | 0.190 |
Why?
|
| Female | 15 | 2024 | 48702 | 0.190 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 103 | 0.190 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 286 | 0.190 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2019 | 19 | 0.190 |
Why?
|
| Kinetics | 4 | 2019 | 1492 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 1395 | 0.190 |
Why?
|
| Nuclear Pore | 1 | 2022 | 12 | 0.190 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2022 | 14 | 0.190 |
Why?
|
| RNA Transport | 1 | 2022 | 11 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2025 | 308 | 0.190 |
Why?
|
| Tryptophan | 1 | 2023 | 105 | 0.190 |
Why?
|
| Male | 13 | 2024 | 44557 | 0.190 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 16 | 0.180 |
Why?
|
| Quality of Life | 2 | 2024 | 1780 | 0.180 |
Why?
|
| Camelids, New World | 1 | 2021 | 4 | 0.180 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 192 | 0.180 |
Why?
|
| Camelus | 1 | 2021 | 5 | 0.180 |
Why?
|
| Sequence Analysis, Protein | 1 | 2021 | 28 | 0.180 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 65 | 0.170 |
Why?
|
| Fungal Proteins | 1 | 2022 | 145 | 0.170 |
Why?
|
| Cytoplasm | 1 | 2022 | 278 | 0.170 |
Why?
|
| Multiprotein Complexes | 1 | 2022 | 106 | 0.170 |
Why?
|
| GATA6 Transcription Factor | 1 | 2021 | 13 | 0.170 |
Why?
|
| Lipids | 1 | 2023 | 278 | 0.170 |
Why?
|
| Heat-Shock Proteins, Small | 1 | 2021 | 1 | 0.170 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 14 | 0.170 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 439 | 0.170 |
Why?
|
| Sodium | 1 | 2022 | 329 | 0.170 |
Why?
|
| Mutation | 4 | 2019 | 4272 | 0.170 |
Why?
|
| Sequence Alignment | 1 | 2021 | 352 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2025 | 438 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 70 | 0.170 |
Why?
|
| Dioxygenases | 1 | 2021 | 82 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2023 | 467 | 0.170 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 155 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 641 | 0.160 |
Why?
|
| Protein Engineering | 2 | 2021 | 150 | 0.160 |
Why?
|
| Frizzled Receptors | 1 | 2020 | 14 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 161 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 660 | 0.160 |
Why?
|
| Quarantine | 1 | 2020 | 9 | 0.160 |
Why?
|
| Amyloid | 1 | 2021 | 104 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2021 | 3502 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 3110 | 0.160 |
Why?
|
| Propylamines | 1 | 2020 | 7 | 0.160 |
Why?
|
| Publications | 1 | 2020 | 32 | 0.160 |
Why?
|
| Dermis | 1 | 2020 | 30 | 0.160 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 5 | 0.160 |
Why?
|
| 5-Methylcytosine | 1 | 2021 | 121 | 0.160 |
Why?
|
| Animals | 10 | 2024 | 28155 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2019 | 1524 | 0.160 |
Why?
|
| Biomimetic Materials | 1 | 2020 | 25 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 78 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 409 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2020 | 9099 | 0.150 |
Why?
|
| Hydrogels | 1 | 2020 | 92 | 0.150 |
Why?
|
| Adult | 7 | 2024 | 27918 | 0.150 |
Why?
|
| Ligands | 2 | 2018 | 476 | 0.150 |
Why?
|
| Mice | 8 | 2024 | 12269 | 0.150 |
Why?
|
| beta-Cyclodextrins | 1 | 2018 | 10 | 0.140 |
Why?
|
| Risk | 1 | 2020 | 657 | 0.140 |
Why?
|
| Apoptosis | 1 | 2025 | 1721 | 0.140 |
Why?
|
| Vitamin E | 1 | 2018 | 34 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 181 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 378 | 0.140 |
Why?
|
| Apoproteins | 1 | 2018 | 22 | 0.140 |
Why?
|
| Burns | 1 | 2020 | 149 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2018 | 88 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2019 | 229 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 224 | 0.140 |
Why?
|
| Antibody Affinity | 1 | 2018 | 38 | 0.140 |
Why?
|
| Substrate Specificity | 3 | 2018 | 363 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 449 | 0.130 |
Why?
|
| Protein Stability | 1 | 2018 | 103 | 0.130 |
Why?
|
| Catalysis | 3 | 2017 | 216 | 0.130 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 21 | 0.130 |
Why?
|
| Liver | 1 | 2022 | 1210 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 149 | 0.130 |
Why?
|
| Carcinoma | 1 | 2020 | 439 | 0.130 |
Why?
|
| Vitamin B 12 | 1 | 2017 | 24 | 0.130 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 504 | 0.130 |
Why?
|
| Cell Membrane | 1 | 2020 | 664 | 0.130 |
Why?
|
| Galactose | 1 | 2016 | 31 | 0.130 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 331 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 202 | 0.130 |
Why?
|
| Duodenum | 1 | 2017 | 110 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 61 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 555 | 0.120 |
Why?
|
| Skin | 1 | 2020 | 578 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 2755 | 0.120 |
Why?
|
| Lectins | 1 | 2016 | 83 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1117 | 0.120 |
Why?
|
| Isoxazoles | 1 | 2016 | 78 | 0.120 |
Why?
|
| Epitope Mapping | 1 | 2016 | 18 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 349 | 0.120 |
Why?
|
| Prednisone | 2 | 2017 | 242 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2021 | 697 | 0.120 |
Why?
|
| Binding Sites | 4 | 2021 | 1133 | 0.120 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 21 | 0.120 |
Why?
|
| Phosphorylation | 3 | 2025 | 1133 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2026 | 0.120 |
Why?
|
| Pyrazines | 1 | 2016 | 93 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 555 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2017 | 158 | 0.120 |
Why?
|
| Neutrophils | 1 | 2017 | 324 | 0.120 |
Why?
|
| Incidence | 1 | 2020 | 1701 | 0.120 |
Why?
|
| Aminopeptidases | 1 | 2015 | 14 | 0.120 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2015 | 9 | 0.120 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 135 | 0.120 |
Why?
|
| Protein Methyltransferases | 1 | 2015 | 15 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2017 | 110 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 52 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2017 | 454 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1234 | 0.110 |
Why?
|
| Glycine | 1 | 2015 | 93 | 0.110 |
Why?
|
| Phosphoglycerate Mutase | 1 | 2015 | 4 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 482 | 0.110 |
Why?
|
| Benchmarking | 1 | 2015 | 80 | 0.110 |
Why?
|
| Histones | 1 | 2017 | 361 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 411 | 0.110 |
Why?
|
| Receptors, Prolactin | 1 | 2015 | 10 | 0.110 |
Why?
|
| Single-Chain Antibodies | 1 | 2015 | 21 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 876 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 920 | 0.110 |
Why?
|
| Research Personnel | 1 | 2015 | 82 | 0.110 |
Why?
|
| Leptin | 1 | 2015 | 100 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 132 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1001 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 313 | 0.110 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 166 | 0.110 |
Why?
|
| Epitopes | 1 | 2015 | 254 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2015 | 321 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 225 | 0.100 |
Why?
|
| Pancreas | 1 | 2015 | 258 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2015 | 163 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 304 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 377 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 203 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2015 | 696 | 0.100 |
Why?
|
| Models, Biological | 1 | 2020 | 1768 | 0.100 |
Why?
|
| Proteins | 1 | 2018 | 803 | 0.090 |
Why?
|
| Androstadienes | 1 | 2012 | 72 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1660 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 379 | 0.090 |
Why?
|
| Cell Line | 1 | 2015 | 2464 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2015 | 867 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1077 | 0.080 |
Why?
|
| Biocatalysis | 1 | 2010 | 55 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 878 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2020 | 4560 | 0.080 |
Why?
|
| Insulin | 1 | 2015 | 1185 | 0.080 |
Why?
|
| Butyric Acid | 1 | 2009 | 12 | 0.080 |
Why?
|
| Maleimides | 1 | 2009 | 27 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 274 | 0.070 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2020 | 101 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 404 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2022 | 657 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2585 | 0.070 |
Why?
|
| Motion | 2 | 2020 | 94 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 526 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 1101 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 402 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2021 | 729 | 0.060 |
Why?
|
| Young Adult | 1 | 2019 | 6930 | 0.060 |
Why?
|
| Adolescent | 1 | 2019 | 9606 | 0.060 |
Why?
|
| Ireland | 1 | 2025 | 12 | 0.060 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 1 | 2025 | 6 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 2017 | 0.060 |
Why?
|
| beta-Arrestin 2 | 1 | 2025 | 5 | 0.060 |
Why?
|
| beta-Arrestin 1 | 1 | 2025 | 6 | 0.060 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2025 | 24 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2025 | 54 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 2910 | 0.060 |
Why?
|
| Receptors, CCR5 | 1 | 2024 | 21 | 0.060 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2024 | 35 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 302 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2017 | 472 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 3830 | 0.050 |
Why?
|
| Hepatitis Delta Virus | 1 | 2024 | 11 | 0.050 |
Why?
|
| Prognosis | 3 | 2017 | 3911 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2022 | 1729 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2024 | 74 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2024 | 47 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2024 | 45 | 0.050 |
Why?
|
| Cisplatin | 2 | 2017 | 568 | 0.050 |
Why?
|
| Sun Protection Factor | 1 | 2023 | 2 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2024 | 129 | 0.050 |
Why?
|
| Anions | 1 | 2023 | 30 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 188 | 0.050 |
Why?
|
| Free Radicals | 1 | 2023 | 71 | 0.050 |
Why?
|
| Chaetomium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Glycosylation | 1 | 2023 | 137 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2023 | 169 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 67 | 0.050 |
Why?
|
| Phthalazines | 1 | 2022 | 53 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2022 | 66 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 87 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1775 | 0.040 |
Why?
|
| Mitosis | 1 | 2022 | 150 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 125 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 30 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2495 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2021 | 26 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2021 | 40 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2024 | 364 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 196 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2022 | 198 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 397 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 161 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 554 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 109 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 319 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 413 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 280 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 1061 | 0.040 |
Why?
|
| Urothelium | 1 | 2020 | 67 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2020 | 111 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2019 | 16 | 0.040 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2019 | 17 | 0.040 |
Why?
|
| Elasticity | 1 | 2020 | 98 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 394 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 126 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2019 | 86 | 0.040 |
Why?
|
| Peptides | 1 | 2023 | 656 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 824 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 761 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2019 | 587 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Arrestin | 1 | 2018 | 5 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2018 | 154 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 256 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2019 | 422 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 39 | 0.030 |
Why?
|
| Zirconium | 1 | 2017 | 2 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2017 | 39 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 163 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3435 | 0.030 |
Why?
|
| Methylmalonic Acid | 1 | 2017 | 7 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1587 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 30 | 0.030 |
Why?
|
| Cetuximab | 1 | 2017 | 118 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2017 | 54 | 0.030 |
Why?
|
| Temperature | 1 | 2018 | 424 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2019 | 563 | 0.030 |
Why?
|
| Gels | 1 | 2016 | 51 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 126 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 104 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 64 | 0.030 |
Why?
|
| Circular Dichroism | 1 | 2016 | 117 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2016 | 307 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 674 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1338 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 1301 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1448 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 762 | 0.030 |
Why?
|
| Switzerland | 1 | 2015 | 19 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 367 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1518 | 0.030 |
Why?
|
| Prolactin | 1 | 2015 | 89 | 0.030 |
Why?
|
| Manganese | 1 | 2015 | 56 | 0.030 |
Why?
|
| Human Growth Hormone | 1 | 2015 | 51 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2015 | 131 | 0.030 |
Why?
|
| North America | 1 | 2015 | 195 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 181 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 149 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 204 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 829 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2016 | 208 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 304 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 109 | 0.020 |
Why?
|
| Feeding and Eating Disorders | 1 | 2015 | 185 | 0.020 |
Why?
|
| Abiraterone Acetate | 1 | 2012 | 11 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 1948 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 1531 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 621 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2016 | 404 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 152 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5410 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 811 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 617 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2015 | 1118 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 3054 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1910 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2802 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 10164 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3476 | 0.010 |
Why?
|
| United States | 1 | 2016 | 7622 | 0.010 |
Why?
|